Sunday 18 October 2026
Export ABEO’s income statement to Excel — free account
Abeona Therapeutics Inc.
ABEO Healthcare Biotechnology
Abeona Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.8 million, up 66.3% from fiscal 2023. In the quarter to June 2026, revenue grew 225.1%, EPS fell 116.9%, free cash flow grew 17.1% and total debt fell 23.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
4.43
0.22
−4.73%
Follow ABEO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 3.58 | 4.02 | — |
+8 more quarters Free account |
P/S ratio |
13.60 | 14.06 | 29.73 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(20.15) | (12.81) | (15.54) | — | |
P/B ratio |
2.75 | 1.75 | 1.75 | — | |
Price to Tangible BV |
2.78 | 1.77 | 1.77 | — | |
EV/Sales |
8.52 | 5.74 | 11.47 | — | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | |
EV/Operating CF |
(2.89) | (1.33) | (1.41) | — | |
EV/FCF |
(2.71) | (1.21) | (1.28) | — | |
Quick Ratio |
6.32 | 5.64 | 6.70 | 9.43 | |
Current Ratio |
6.63 | 5.89 | 6.93 | 9.74 | |
Net Debt/EBITDA |
10.28 | 6.78 | 7.85 | 8.12 | |
Debt/Assets |
8.35% | 9.11% | 9.12% | 8.55% | |
Debt/Equity |
0.12 | 0.12 | 0.13 | 0.12 | |
Asset Turnover |
0.12 | 0.12 | 0.06 | 0.00 | |
Operating CF/Net income |
0.87 | 1.16 | 0.88 | 4.11 | |
Capex/Depreciation |
(0.57) | (1.08) | (1.06) | (2.84) | |
Interest Coverage |
(19.62) | (27.75) | (25.92) | (26.66) | |
Research and Development Expense of Revenue |
44.12% | 109.58% | 123.84% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
139.15% | 223.65% | 346.53% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
76.93% | (27.86%) | 47.21% | 0.00% | |
Graham Net Nets |
0.32 | 0.51 | 0.52 | — | |
Graham Number |
0.00 | 8.49 | 9.41 | — | |
Earnings Yield |
(18.93%) | 27.90% | 24.86% | — | |
Free Cash Flow Yield |
(23.12%) | (33.60%) | (30.21%) | — | |
Revenue per Share |
0.20 | 0.15 | 0.10 | 0.00 | |
Operating CF per Share |
(0.31) | (0.35) | (0.34) | (0.39) | |
Capex per Share |
(0.01) | (0.02) | (0.02) | (0.05) | |
Free Cash Flow per Share |
(0.32) | (0.37) | (0.36) | (0.44) | |
Cash per Share |
2.57 | 2.97 | 3.61 | 3.82 | |
Shareholders Equity per Share |
2.24 | 2.56 | 3.01 | 3.16 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.24 | 2.56 | 3.01 | 3.16 | |
Free Cash Flow |
(17.97) | (20.74) | (19.11) | (23.71) | |
Working Capital |
139.77 | 151.94 | 175.34 | 193.95 | |
Capital Expenditures |
(0.48) | (0.93) | (1.15) | (2.52) | |
Net Current Asset Value |
113.13 | 129.43 | 144.55 | 156.27 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
0.04 | 0.11 | 0.21 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
5.76 | 4.16 | 4.18 | 1.61 | |
Average Payables |
5.17 | 4.54 | 5.67 | 4.36 | |
Average Inventory |
4.30 | — | — | — | |
Average Assets |
212.87 | 148.93 | 164.25 | 175.84 | |
Average Common Equity |
145.82 | 93.17 | 101.62 | 108.50 |
Columns are period end dates